REG - AstraZeneca PLC - Directorate change

AstraZenecaAnnouncement

23/04/2026 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260423:nRSW5391Ba&default-theme=true

RNS Number : 5391B  AstraZeneca PLC  23 April 2026

23 April 2026

Change to AstraZeneca Board of Directors

 

AstraZeneca congratulates Rene Haas on his appointment as Chief Executive
Officer of SoftBank Group International, in addition to his position as Chief
Executive Officer of Arm Holdings plc. Taking into account this additional
workload, we have mutually agreed that Rene will not have enough time
available to fully assume his AstraZeneca Board member duties. He will step
down as a Non-Executive Director of AstraZeneca PLC on 30 April 2026, as he
takes up his new appointment.

 

Michel Demaré, Chair of AstraZeneca, said "On behalf of the whole Board, I
would like to thank Rene for his contributions drawing on his considerable
business acumen and extensive experience of data science, computing and AI. We
wish him all the best for his future endeavours."

 

For the purposes of section 430(2B) of the Companies Act 2006, other than
non-executive director fees for his time on the Board, Rene will not receive
any remuneration or payment for loss of office.

 

AstraZeneca (https://www.astrazeneca.com/)

AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical
company that focuses on the discovery, development, and commercialisation of
prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals,
including Cardiovascular, Renal & Metabolism, and Respiratory &
Immunology. Based in Cambridge, UK, AstraZeneca's innovative medicines are
sold in more than 125 countries and used by millions of patients worldwide.
Please visit astrazeneca.com (http://www.astrazeneca.com/) and follow the
Company on Social Media @AstraZeneca
(https://www.linkedin.com/company/astrazeneca) .

 

 

Contacts

For details on how to contact the Investor Relations Team, please click here
(https://www.astrazeneca.com/investor-relations.html#Contacts) . For Media
contacts, click here (https://www.astrazeneca.com/media-centre/contacts.html)
.

 

 

 

 

Matthew Bowden

Company Secretary

AstraZeneca PLC

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOASEAFLEEMSEFL



            Copyright 2019 Regulatory News Service, all rights reserved